JPWO2021146222A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021146222A5
JPWO2021146222A5 JP2022542899A JP2022542899A JPWO2021146222A5 JP WO2021146222 A5 JPWO2021146222 A5 JP WO2021146222A5 JP 2022542899 A JP2022542899 A JP 2022542899A JP 2022542899 A JP2022542899 A JP 2022542899A JP WO2021146222 A5 JPWO2021146222 A5 JP WO2021146222A5
Authority
JP
Japan
Prior art keywords
molecules
engineered cell
gene
mhc
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542899A
Other languages
English (en)
Japanese (ja)
Other versions
JP7853210B2 (ja
JP2023510872A5 (https=
JP2023510872A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013140 external-priority patent/WO2021146222A1/en
Publication of JP2023510872A publication Critical patent/JP2023510872A/ja
Publication of JP2023510872A5 publication Critical patent/JP2023510872A5/ja
Publication of JPWO2021146222A5 publication Critical patent/JPWO2021146222A5/ja
Application granted granted Critical
Publication of JP7853210B2 publication Critical patent/JP7853210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542899A 2020-01-13 2021-01-12 血液型抗原の修飾 Active JP7853210B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062960607P 2020-01-13 2020-01-13
US202062960617P 2020-01-13 2020-01-13
US62/960,617 2020-01-13
US62/960,607 2020-01-13
PCT/US2021/013140 WO2021146222A1 (en) 2020-01-13 2021-01-12 Modification of blood type antigens

Publications (4)

Publication Number Publication Date
JP2023510872A JP2023510872A (ja) 2023-03-15
JP2023510872A5 JP2023510872A5 (https=) 2024-01-22
JPWO2021146222A5 true JPWO2021146222A5 (https=) 2024-01-22
JP7853210B2 JP7853210B2 (ja) 2026-04-28

Family

ID=

Similar Documents

Publication Publication Date Title
Sedlik et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells
Busche et al. Priming of CD8+ T cells against cytomegalovirus-encoded antigens is dominated by cross-presentation
Kohn et al. New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing
JP6816031B2 (ja) 非標準的なcd8+t細胞応答を生成するのに有用な方法および組成物
JP2023002716A (ja) 主要組織適合遺伝子複合体e分子によって拘束されるt細胞を誘発するサイトメガロウイルスベクター及びhcmvベクターを含む組成物
Aslanidi et al. High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors
JP7523357B2 (ja) ウイルスベクター産生
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CN114072516A (zh) 经修饰的腺病毒
JP2015506365A (ja) Cd4+t細胞応答を向上するための修飾されたエピトープ
AU2016328582A1 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
WO2017087921A1 (en) Cmv vectors comprising microrna recognition elements
CN116033910A (zh) 编辑b细胞中b2m基因座的方法和组合物
Crivello et al. Multiple knockout of classical HLA class II β-chains by CRISPR/Cas9 genome editing driven by a single guide RNA
Cervantes-Barragan et al. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity
Kleinstiver et al. 731. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
US20060073123A1 (en) Adenovirus vectors for immunotherapy
Vanniasinkam et al. DNA immunization using a non-viral promoter
Roy Immune responses to CRISPR-Cas protein
JPWO2023019203A5 (https=)
JPWO2021146222A5 (https=)
AU2020370254B2 (en) Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
Reimann et al. Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains
JP7714667B2 (ja) 改変ヒト人工多能性幹細胞の製造方法